Why the study?
The study was conducted to analyse the safety and efficacy of direct oral anticoagulants in real-world studies of atrial fibrillation patients.
Does the choice of DOAC affect the risk of bleeding and thromboembolic events in real-world patients with atrial fibrillation?
Population
605 771 AF patients across 21 observational studies
Comparison
Apixaban vs rivaroxaban vs dabigatran
Design
Systematic review and Bayesian random-effects network meta-analysis
Authors
Loading...
Real-world data highlight differential bleeding risks among DOACs in AF; leaves open optimal agent selection pending randomized confirmation.
Does the choice of DOAC affect the risk of bleeding and thromboembolic events in real-world patients with atrial fibrillation?
In real-world patients with atrial fibrillation, apixaban demonstrates a more favorable safety profile regarding major and GI bleeding compared to rivaroxaban and dabigatran, while maintaining similar efficacy.
Menichelli et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: